These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 26681807)
1. AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease. Vázquez-Manrique RP; Farina F; Cambon K; Dolores Sequedo M; Parker AJ; Millán JM; Weiss A; Déglon N; Neri C Hum Mol Genet; 2016 Mar; 25(6):1043-58. PubMed ID: 26681807 [TBL] [Abstract][Full Text] [Related]
2. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease. Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181 [TBL] [Abstract][Full Text] [Related]
3. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. Ju TC; Chen HM; Lin JT; Chang CP; Chang WC; Kang JJ; Sun CP; Tao MH; Tu PH; Chang C; Dickson DW; Chern Y J Cell Biol; 2011 Jul; 194(2):209-27. PubMed ID: 21768291 [TBL] [Abstract][Full Text] [Related]
4. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145 [TBL] [Abstract][Full Text] [Related]
5. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446 [TBL] [Abstract][Full Text] [Related]
6. Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. Jin J; Gu H; Anders NM; Ren T; Jiang M; Tao M; Peng Q; Rudek MA; Duan W Neuromolecular Med; 2016 Dec; 18(4):581-592. PubMed ID: 27225841 [TBL] [Abstract][Full Text] [Related]
7. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease. Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363 [TBL] [Abstract][Full Text] [Related]
8. Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington's disease. Jiang M; Zhang X; Liu H; LeBron J; Alexandris A; Peng Q; Gu H; Yang F; Li Y; Wang R; Hou Z; Arbez N; Ren Q; Dong JL; Whela E; Wang R; Ratovitski T; Troncoso JC; Mori S; Ross CA; Lim J; Duan W Hum Mol Genet; 2020 May; 29(8):1340-1352. PubMed ID: 32242231 [TBL] [Abstract][Full Text] [Related]
10. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype. Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255 [TBL] [Abstract][Full Text] [Related]
11. The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington's disease. Farina F; Lambert E; Commeau L; Lejeune FX; Roudier N; Fonte C; Parker JA; Boddaert J; Verny M; Baulieu EE; Neri C Sci Rep; 2017 Jun; 7(1):4014. PubMed ID: 28638078 [TBL] [Abstract][Full Text] [Related]
12. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402 [TBL] [Abstract][Full Text] [Related]
13. Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model. Wood TE; Barry J; Yang Z; Cepeda C; Levine MS; Gray M Hum Mol Genet; 2019 Feb; 28(3):487-500. PubMed ID: 30312396 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. Wang S; Song P; Zou MH J Biol Chem; 2012 Mar; 287(11):8001-12. PubMed ID: 22267730 [TBL] [Abstract][Full Text] [Related]
15. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. Oliveira JM J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078 [TBL] [Abstract][Full Text] [Related]
16. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease. Liu KY; Shyu YC; Barbaro BA; Lin YT; Chern Y; Thompson LM; James Shen CK; Marsh JL Hum Mol Genet; 2015 Mar; 24(6):1602-16. PubMed ID: 25398943 [TBL] [Abstract][Full Text] [Related]
17. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Saavedra A; García-Martínez JM; Xifró X; Giralt A; Torres-Peraza JF; Canals JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E Cell Death Differ; 2010 Feb; 17(2):324-35. PubMed ID: 19745829 [TBL] [Abstract][Full Text] [Related]
18. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. Tong JF; Yan X; Zhu MJ; Du M J Cell Biochem; 2009 Oct; 108(2):458-68. PubMed ID: 19639604 [TBL] [Abstract][Full Text] [Related]
19. Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells. Jen WP; Chen HM; Lin YS; Chern Y; Lee YC Mol Neurobiol; 2020 Mar; 57(3):1688-1703. PubMed ID: 31813126 [TBL] [Abstract][Full Text] [Related]
20. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]